Evidence map›Paper›PMID 35809080›Full record

ArticleThe Australasian journal of dermatology2022

Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).

Peter Foley, Nick Manuelpillai, Con Dolianitis, Geoffrey D Cains, Eric Mate, Rebecca Tronnberg, Christopher Baker

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Australasian journal of dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Peter FoleySkin Health Institute, Carlton, Victoria, Australia.ORCID https://orcid.org/0000-0001-5891-5607
Nick ManuelpillaiSkin Health Institute, Carlton, Victoria, Australia.ORCID https://orcid.org/0000-0002-4043-1281
Con DolianitisThe University of Melbourne, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
Geoffrey D CainsLiverpool Hospital, Sydney, New South Wales, Australia.
Eric MateNovartis Pharmaceuticals, Australia Pty Limited, Macquarie Park, New South Wales, Australia.
Rebecca TronnbergNovartis Pharmaceuticals, Australia Pty Limited, Macquarie Park, New South Wales, Australia.
Christopher BakerSkin Health Institute, Carlton, Victoria, Australia.
Novartis (Australia) · AUThe University of Melbourne · AULiverpool Hospital · AUSkin Health Institute · AUThe Royal Melbourne Hospital · AU

Funding

The University of MelbourneThis investigation was sponsored by Novartis Pharmaceuticals Australia Pty Ltd.
6 · The paper itself

Abstract

backgroundDrug survival measures the rate and duration of adherence to a given therapeutic agent and evaluates its long-term effectiveness, safety, and real-world utility. The SUSTAIN study sought to establish the drug survival and effectiveness of secukinumab for patients with severe chronic plaque psoriasis (CPP) in the Australian clinical setting.

methodsData of all patients (aged ≥18 years) from Australasian Psoriasis Registry (APR) treated with secukinumab were analysed. The primary objective was to describe the drug survival of secukinumab at 9 months. Key secondary objectives included drug survival of secukinumab at 3, 6, 15, and 21 months, stratified by biologic-naïve vs biologic-experienced patients; proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75/90/100 responses; and changes in health-related quality of life over time utilising the Dermatology Life Quality Index (DLQI).

resultsOf 294 patients included in this analysis, 110 (37.4%) were biologic-naïve and 184 (62.6%) biologic-experienced. Kaplan-Meїer drug survival rates in biologic-naïve vs biologic-experienced patients were 0.92 vs. 0.86 (9 months) and 0.82 vs. 0.68 (21 months), respectively. The proportion of patients with PASI 75/90/100 responses for biologic-naïve vs. biologic-experienced was 100/87.7/38.4 vs 98.5/61.5/27.2 (9 months) and 100/81.0/41.7 vs. 98.4/62.0/24.2 (21 months), respectively. The mean (standard deviation [SD]) DLQI in biologic-naïve vs. experienced patients was 2.2 (4.1) vs. 3.1 (5.2) (9 months) and 1.4 (2.5) vs. 3.1 (5.3) (21 months). No new safety signals were observed.

conclusionsSecukinumab demonstrated high drug survival and sustained effectiveness in Australian real-world setting, in biologic-naïve and biologic-experienced patients with severe CPP.

Indexed as

Biological ProductsPsoriasisAdolescentAdultAntibodies, Monoclonal, HumanizedAustraliaHumansQuality of LifeSeverity of Illness IndexTreatment OutcomeAntibodies, Monoclonal, HumanizedBiological ProductssecukinumabAustraliadrug survivaldurabilitypsoriasisreal-world and clinical settingsecukinumab

Identifiers

PMID35809080
PMCPMC9543110
OpenAlexW4284972801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.